AstraZeneca: Tagrisso Achieved Unprecedented Survival in Early-Stage EGFR-Mutated Lung Cancer, With 88% of Patients Alive at Five Years in Adaura Phase III Trial
June 05, 2023
June 05, 2023
WILMINGTON, Delaware, June 5 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on June 4, 2023:
Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small . . .
Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small . . .